Fully human anti-CD19 CAR T cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies that lead to immune complex-induced inflammation in an array of different organs including the kidneys, heart, lungs and skin. The pathogenesis of SLE is complex and relies on genetic, endogenous, environmental and immunoregulatory factors1. The central role of B cells in SLE is supported by the presence of B cells in diseased tissues, clonal expansion and plasmablast generation. Monoclonal antibodies that disrupt B cell activation or deplete B cells have been used to treat autoimmune diseases like SLE. (Source: Bio...
Source: Biology of Blood and Marrow Transplantation - March 26, 2024 Category: Hematology Authors: Janin Dingfelder, Michael Aigner, Jule Taubmann, Ioanna Minopoulou, Soo Park, Charles D. Kaplan, Joseph K. Cheng, Tom Van Blarcom, Georg Schett, Andreas Mackensen, Gloria Lutzny-Geier Source Type: research
Rheumatic diseases in migrant patients resident in Tuscany: epidemiological data analysis and single-center experience
CONCLUSIONS: This study provides a picture of the rheumatic diseases affecting foreign patients residing in Tuscany that are in agreement with the epidemiological data previously provided.PMID:38523585 | DOI:10.4081/reumatismo.2024.1547 (Source: Reumatismo)
Source: Reumatismo - March 25, 2024 Category: Rheumatology Authors: L Cometi P Francesconi B Bellini L Turco F Voller F Nacci S Bellando-Randone M Matucci-Cerinic S Guiducci Source Type: research
A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases.PMID:38524393 | PMC:PMC10961069 | DOI:10.2147/CCID.S448535 (Source: Clini...
Source: Clinical, Cosmetic and Investigational Dermatology - March 25, 2024 Category: Dermatology Authors: Qingxia Lin Jinrong Zhu Xuelei Gao Source Type: research
A large cohort comparison of very late-onset systemic lupus erythematosus with younger-onset patients
CONCLUSIONS: Compared with younger patients, in vlSLE, female predominance is less pronounced. Arthritis, anti-dsDNA antibodies and low C3 levels are less frequent. SS and RA are more common. Despite lower disease activity, vlSLE patients have the lowest survival rate. While uncommon, SLE should not be excluded as a possible diagnosis in the elderly.PMID:38526004 | DOI:10.55563/clinexprheumatol/jgsyos (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 25, 2024 Category: Rheumatology Authors: Luisa Viveiros Ana Neves Teresa Gouveia David A Isenberg Source Type: research
Rilonacept use in lupus pericarditis
CONCLUSIONS: Rilonacept successfully treated lupus pericarditis in this case series. Rilonacept should be considered for the treatment of lupus pericarditis.PMID:38526001 | DOI:10.55563/clinexprheumatol/pb3hzb (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 25, 2024 Category: Rheumatology Authors: Andrea Fava Michael Cammarata Luigi Adamo Source Type: research